Help Prevent the Flu After Exposure ¹

In Trial 4, conducted in Japan, 607 subjects (XOFLUZA n=303, placebo n=304) ≥12 years of age were randomized to receive a single oral dose of XOFLUZA, based on body weight and age, or placebo. In total, 374 subjects were treated with XOFLUZA and 375 with placebo. Subjects aged ≥12 years received 40 mg or 80 mg of XOFLUZA according to body weight. Subjects aged <12 years were dosed according to body weight. Subjects were household members of influenza-infected index patients and were required to have lived with the influenza-infected index patient for ≥48 hours. Index patients were required to have onset of symptoms for ≤48 hours. The primary efficacy endpoint was the proportion of household subjects who were infected with influenza virus and presented with fever and ≥1 respiratory symptom (cough or nasal discharge/nasal congestion assessed by the subject as moderate or severe) from day 1 to day 10. The proportion of subjects ≥12 years of age who met the primary endpoint was 1% (95% CI: 0.4, 3.3) in the XOFLUZA group and 13% (95% CI: 9.6, 17.5) in the placebo group, corresponding to an estimated adjusted risk ratio of 0.10 (95% CI: 0.04, 0.28), based on randomization factors. ^1,11

 

XOFLUZA keeps flu treatment simple with one single dose compared to 10 doses with oseltamivir for the treatment or post-exposure prevention of the flu. ^1,2 Learn more